Propofol promotes apoptosis and suppresses the HOTAIR-mediated mTOR/p70S6K signaling pathway in melanoma cells

Shang, Zhiwei; Feng, Haixia; Cui, Lisha; Wang, Weiping; Fu, Hongwei

doi:10.3892/ol.2017.7297

Cited by 13 publications

(14 citation statements)

References 26 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the use of propofol in tumor surgery may be beneficial. apoptosis (Shang, Feng, Cui, Wang, & Fu, 2018). Our work complements another study (Shang et al, 2018) 2018).…”

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

Propofol suppresses proliferation, invasion, and migration of human melanoma cells via regulating microRNA‐137 and fibroblast growth factor 9

Zhou

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Propofol is an intravenous anesthetic widely used in clinical surgeries, such as tumor resection. Propofol affects the growth of many cancers, though its effect on melanoma is unknown. Our study aimed to explore how propofol affects melanoma cells. Melanoma cells A2058 and WM793B were cultured with propofol for 24 hr.Propofol significantly suppressed proliferation, migration, and invasion of A2058 and WM793B cells. Lower miR-137 level was observed in A2058 and WM793B cells, compared with normal human epidermal melanocyte HEMa-LP cells. Propofolinduced miR-137 upregulation and decreased proliferation, invasive ability, and migrated ability of A2058 and WM793B cells. Transfection with the miR-137 inhibitor reversed these effects. Additionally, miR-137 was verified to target and negatively regulate fibroblast growth factor 9 (FGF9) expression. Propofol efficiently downregulated FGF9 protein expression by upregulating miR-137. Furthermore, FGF9 overexpression abrogated propofol's repressive effects on the malignant potential of A2058 and WM793B cells. These findings indicate that propofol suppressed melanoma cell proliferation, invasion, and migration by regulating miR-137 and FGF9.

show abstract

“…Therefore, the use of propofol in tumor surgery may be beneficial. apoptosis (Shang, Feng, Cui, Wang, & Fu, 2018). Our work complements another study (Shang et al, 2018) 2018).…”

Section: Discussionsupporting

confidence: 79%

“…apoptosis (Shang, Feng, Cui, Wang, & Fu, 2018). Our work complements another study (Shang et al, 2018) 2018). miR-137 acts as a tumor suppressor in various human cancers (R. Chen, Zhang, Zhang, Wu, & Yang, 2017;Du et al, 2016;Peres et al, 2017).…”

Section: Discussionsupporting

confidence: 79%

Propofol suppresses proliferation, invasion, and migration of human melanoma cells via regulating microRNA‐137 and fibroblast growth factor 9

Zhou

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…It is well known that epigenetic alterations or genetic modulation of epigenetic regulators plays important roles in carcinogenesis . Many studies show that the anticancer effect of propofol is potentially due to regulation of the epigenetic pathway in cancer …”

Section: Epigenetic Pathwaysmentioning

confidence: 99%

“…29 Shang et al also proved that propofol promotes apoptosis in melanoma cells by suppressing the HOTAIR-mediated mTOR/p70S6K signaling pathway. 30 A recent study reported that the lncRNA XIST was dysregulated in different cancers and associated with poor clinical outcome. [31][32][33][34] Chen et al…”

Section: Propofol and Lncrnamentioning

confidence: 99%

The mechanism of propofol in cancer development: An updated review

Gao

Guo

et al. 2020

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

Cancer is a key cause of death worldwide. Despite the development of radiotherapy, chemotherapy and even immunotherapy, surgery remains the standard treatment for cancer patients. Recently, many studies have shown that propofol, a commonly used anesthetic drug, can affect the prognosis of cancer. In this review, we provide an overview of the molecular mechanisms of propofol in the development of cancer. Propofol not only affects epigenetic pathways, such as those involving miRNA, lncRNA and histone acetylation, but also modulates genetic signaling pathways, including the hypoxia, NF‐κB, MAPK, SLUG and Nrf2 pathways. In addition, propofol influences the immune function of patients and impacts the degree of immunosuppression. Furthermore, we briefly summarize the clinical trials on the effect of propofol in cancer development. Ultimately, further studies distinguishing the types of tumors in clinical trials are needed to clarify the correlation between propofol and cancer.

show abstract

“…Exposure to halothane and isoflurane, when compared with oxygen, was correlated to an increased number of lung metastasis in C57BL mice model injected with B16 melanoma cells 16. In contrast, propofol induced apoptosis of B16F10 melanoma cells ‘in vitro’ 17. Lidocaine and ropivacaine reduced the viability of melanoma cells and increased apoptosis in a concentration-dependent manner ‘in vitro’ 18.…”

Section: Introductionmentioning

confidence: 99%

Impact of general anaesthesia in overall and disease-free survival compared to other types of anaesthesia in patients undergoing surgery for cutaneous melanoma: a systematic review and meta-analysis protocol

Araujo

Oliveira

Corrêa³

et al. 2019

BMJ Open

View full text Add to dashboard Cite

IntroductionCutaneous melanoma is an aggressive type of skin cancer. Anaesthetic agents may have an impact on the immune response, postoperative neurohumoral response and tumour progression. This systematic review aims to evaluate the impact of general anaesthesia on overall and disease-free survival compared with other types anaesthesia in patients undergoing surgery for cutaneous melanoma.Methods and analysisThe review will analyse data from controlled and observational studies of patients undergoing surgery for melanoma under general anaesthesia compared with other types of anaesthesia. The primary outcomes are overall survival and disease-free survival. The secondary outcomes are health-related quality of life, time to tumour progression, distant disease-free survival, time to treatment failure, cancer-specific survival, biochemical recurrence, return of intended oncological therapy, days alive and out of the hospital at 90 days, cost analysis and adverse events. A comprehensive literature search will be performed using the MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science, LILACS and IBECS databases. Grey literature will also be searched. Risk of methodological bias will be assessed using The Cochrane Collaboration’s revised tool for assessing risk of bias in randomised trials (RoB 2.0) and the Newcastle–Ottawa scale. Two reviewers will independently assess the eligibility of studies and risk of bias; a third author will solve discrepancies. One author will perform data extraction and the other will check the process and data. Qualitative analysis will be carried out using all included studies. A meta-analysis using a random-effects model for pooled risk estimates will be carried out for the two main outcomes and for selected secondary outcomes if they conform to previously stated criteria. The GRADE approach will be used to summarise the quality of evidence.Ethics and disseminationEthics approval is not required as we analyse data from previously reported studies.PROSPERO registration numberCRD42018114918.

show abstract

Propofol promotes apoptosis and suppresses the HOTAIR-mediated mTOR/p70S6K signaling pathway in melanoma cells

Cited by 13 publications

References 26 publications

Propofol suppresses proliferation, invasion, and migration of human melanoma cells via regulating microRNA‐137 and fibroblast growth factor 9

Propofol suppresses proliferation, invasion, and migration of human melanoma cells via regulating microRNA‐137 and fibroblast growth factor 9

The mechanism of propofol in cancer development: An updated review

Impact of general anaesthesia in overall and disease-free survival compared to other types of anaesthesia in patients undergoing surgery for cutaneous melanoma: a systematic review and meta-analysis protocol

Contact Info

Product

Resources

About